vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and 1ST SOURCE CORP (SRCE). Click either name above to swap in a different company.

1ST SOURCE CORP is the larger business by last-quarter revenue ($113.1M vs $75.5M, roughly 1.5× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 8.7%). 1ST SOURCE CORP produced more free cash flow last quarter ($58.1M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 7.8%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

1st Source Corporation is a financial services company headquartered in South Bend, Indiana. It operates 1st Source Bank, a bank with 81 branches in Indiana and Michigan. The bank's Specialty Finance Group provides financing for aircraft, trucks, and construction equipment. 1st Source Insurance provides insurance products and services.

PBYI vs SRCE — Head-to-Head

Bigger by revenue
SRCE
SRCE
1.5× larger
SRCE
$113.1M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+19.0% gap
PBYI
27.7%
8.7%
SRCE
More free cash flow
SRCE
SRCE
$43.7M more FCF
SRCE
$58.1M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
7.8%
SRCE

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
PBYI
PBYI
SRCE
SRCE
Revenue
$75.5M
$113.1M
Net Profit
$40.0M
Gross Margin
69.3%
Operating Margin
22.7%
45.4%
Net Margin
35.3%
Revenue YoY
27.7%
8.7%
Net Profit YoY
6.5%
EPS (diluted)
$0.26
$1.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
SRCE
SRCE
Q1 26
$113.1M
Q4 25
$75.5M
$110.8M
Q3 25
$54.5M
$110.7M
Q2 25
$52.4M
$108.2M
Q1 25
$46.0M
$104.0M
Q4 24
$59.1M
$97.8M
Q3 24
$80.5M
$97.9M
Q2 24
$47.1M
$97.3M
Net Profit
PBYI
PBYI
SRCE
SRCE
Q1 26
$40.0M
Q4 25
$41.1M
Q3 25
$8.8M
$42.3M
Q2 25
$5.9M
$37.3M
Q1 25
$3.0M
$37.5M
Q4 24
$31.4M
Q3 24
$20.3M
$34.9M
Q2 24
$-4.5M
$36.8M
Gross Margin
PBYI
PBYI
SRCE
SRCE
Q1 26
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Operating Margin
PBYI
PBYI
SRCE
SRCE
Q1 26
45.4%
Q4 25
22.7%
Q3 25
17.6%
49.7%
Q2 25
12.7%
44.5%
Q1 25
8.7%
45.8%
Q4 24
22.6%
Q3 24
27.4%
46.3%
Q2 24
-4.6%
49.1%
Net Margin
PBYI
PBYI
SRCE
SRCE
Q1 26
35.3%
Q4 25
37.1%
Q3 25
16.2%
38.2%
Q2 25
11.2%
34.5%
Q1 25
6.5%
36.1%
Q4 24
32.1%
Q3 24
25.2%
35.7%
Q2 24
-9.6%
37.8%
EPS (diluted)
PBYI
PBYI
SRCE
SRCE
Q1 26
$1.63
Q4 25
$0.26
$1.67
Q3 25
$0.17
$1.71
Q2 25
$0.12
$1.51
Q1 25
$0.06
$1.52
Q4 24
$0.40
$1.27
Q3 24
$0.41
$1.41
Q2 24
$-0.09
$1.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
SRCE
SRCE
Cash + ST InvestmentsLiquidity on hand
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$130.3M
$1.3B
Total Assets
$216.3M
$9.1B
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
SRCE
SRCE
Q1 26
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Total Debt
PBYI
PBYI
SRCE
SRCE
Q1 26
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Stockholders' Equity
PBYI
PBYI
SRCE
SRCE
Q1 26
$1.3B
Q4 25
$130.3M
$1.3B
Q3 25
$115.3M
$1.2B
Q2 25
$104.7M
$1.2B
Q1 25
$97.1M
$1.2B
Q4 24
$92.1M
$1.1B
Q3 24
$71.1M
$1.1B
Q2 24
$48.5M
$1.0B
Total Assets
PBYI
PBYI
SRCE
SRCE
Q1 26
$9.1B
Q4 25
$216.3M
$9.1B
Q3 25
$202.9M
$9.1B
Q2 25
$194.9M
$9.1B
Q1 25
$196.2M
$9.0B
Q4 24
$213.3M
$8.9B
Q3 24
$220.7M
$8.8B
Q2 24
$205.0M
$8.9B
Debt / Equity
PBYI
PBYI
SRCE
SRCE
Q1 26
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
SRCE
SRCE
Operating Cash FlowLast quarter
$14.4M
$59.1M
Free Cash FlowOCF − Capex
$14.4M
$58.1M
FCF MarginFCF / Revenue
19.1%
51.4%
Capex IntensityCapex / Revenue
0.0%
0.9%
Cash ConversionOCF / Net Profit
1.48×
TTM Free Cash FlowTrailing 4 quarters
$41.7M
$361.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
SRCE
SRCE
Q1 26
$59.1M
Q4 25
$14.4M
$223.1M
Q3 25
$9.7M
$51.0M
Q2 25
$14.1M
$44.9M
Q1 25
$3.6M
$71.8M
Q4 24
$15.6M
$193.9M
Q3 24
$11.0M
$68.4M
Q2 24
$1.0M
$50.0M
Free Cash Flow
PBYI
PBYI
SRCE
SRCE
Q1 26
$58.1M
Q4 25
$14.4M
$213.0M
Q3 25
$9.7M
$47.3M
Q2 25
$14.1M
$43.0M
Q1 25
$3.6M
$69.3M
Q4 24
$15.6M
$181.5M
Q3 24
$11.0M
$66.7M
Q2 24
$1.0M
$46.4M
FCF Margin
PBYI
PBYI
SRCE
SRCE
Q1 26
51.4%
Q4 25
19.1%
192.2%
Q3 25
17.7%
42.7%
Q2 25
26.8%
39.8%
Q1 25
7.7%
66.6%
Q4 24
26.4%
185.5%
Q3 24
13.7%
68.1%
Q2 24
2.1%
47.7%
Capex Intensity
PBYI
PBYI
SRCE
SRCE
Q1 26
0.9%
Q4 25
0.0%
9.1%
Q3 25
0.0%
3.4%
Q2 25
0.0%
1.7%
Q1 25
0.1%
2.4%
Q4 24
0.0%
12.6%
Q3 24
0.0%
1.7%
Q2 24
0.0%
3.7%
Cash Conversion
PBYI
PBYI
SRCE
SRCE
Q1 26
1.48×
Q4 25
5.42×
Q3 25
1.10×
1.21×
Q2 25
2.41×
1.20×
Q1 25
1.21×
1.91×
Q4 24
6.17×
Q3 24
0.54×
1.96×
Q2 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons